Cargando…

The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a common complication in patients receiving chronic dialysis therapy. Although cinacalcet can control parathyroid function and bone turnover, preventing ectopic calcification remains challenging. Cinacalcet can also suppress PTH secretion due to pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takada, Daisuke, Tsukamoto, Tatsuo, Fuse, Miho, Kada, Shinpei, Yanagita, Motoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648519/ https://www.ncbi.nlm.nih.gov/pubmed/29047366 http://dx.doi.org/10.1186/s12882-017-0733-0

Ejemplares similares

The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma
por: Nadarasa, K, et al.
Publicado: (2014)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction
por: Zitt, Emanuel, et al.
Publicado: (2013)

Case report of a cystic parathyroidal adenoma with rapid growth induced by cinacalcet
por: Werner, Christoph, et al.
Publicado: (2020)

Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide
por: Bech, Anneke, et al.
Publicado: (2012)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Successful use of cinacalcet to treat parathyroid-related hypercalcemia in two pediatric patients
por: Mogas, E, et al.
Publicado: (2018)

SAT-349 Cinacalcet Resistant Tertiary Hyperparathyroidism with One Large Parathyroid Gland
por: Chaker, Bayan, et al.
Publicado: (2020)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy
por: Koda, Ryo, et al.
Publicado: (2014)

Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas
por: Sugi, Orie, et al.
Publicado: (2010)

Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone
por: Shahen, V. A., et al.
Publicado: (2023)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD
por: Miller, Gerald, et al.
Publicado: (2012)

Cinacalcet is effective in the treatment of hyperparathyroidism secondary to malignant transformation of autotransplanted parathyroid tissue. A case report
por: Dattolo, Pietro, et al.
Publicado: (2010)

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
por: Meola, Mario, et al.
Publicado: (2009)

Association Between Resistance to Cinacalcet and Parathyroid Gland Hyperplasia in Kidney Transplant Recipients with Persistent Hypercalcemia
por: Oruc, A., et al.
Publicado: (2020)

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

Recurrent Metastasized Parathyroid Carcinoma—Long‐Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide
por: Storvall, Sara, et al.
Publicado: (2018)

Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients
por: Kim, Jwa-Kyung, et al.
Publicado: (2013)

An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
por: Padhi, Desmond, et al.
Publicado: (2012)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy
por: Bolasco, Piergiorgio, et al.
Publicado: (2010)

The Effect of the Frequently Used Cinacalcet for pHPT during the COVID-19 Pandemic on Perioperative Decrease in Parathyroid Hormone
por: Radulova-Mauersberger, Olga, et al.
Publicado: (2022)

The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate: when should cinacalcet hydrochloride be administered?
por: Date, Toshiyuki, et al.
Publicado: (2008)

Cinacalcet: the chemical parathyroidectomy?
por: Bellasi, Antonio, et al.
Publicado: (2013)

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Behets, Geert J, et al.
Publicado: (2015)

Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Ruderman, Irene, et al.
Publicado: (2018)

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients
por: Lee, Yueh-Ting, et al.
Publicado: (2013)

Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
por: St. Peter, Wendy L, et al.
Publicado: (2015)

Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats
por: Wu-Wong, J Ruth, et al.
Publicado: (2013)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
por: Zheng, Cai-Mei, et al.
Publicado: (2018)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Cinacalcet in HIV haemodialysis patients
por: Belmouaz, Simohamed, et al.
Publicado: (2008)

Hypercalcemia of malignancy treated with cinacalcet
por: Asonitis, Nikolaos, et al.
Publicado: (2017)

Reversible bone pain and symmetric bone scan uptake in a dialysis patient treated with cinacalcet: a case report
por: Lenz, Oliver, et al.
Publicado: (2010)

Dialysis physicians’ referral behaviors for hemodialysis patients suspected of having cancer: A vignette-based questionnaire study
por: Fukuma, Shingo, et al.
Publicado: (2018)

Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study
por: Rottembourg, Jacques, et al.
Publicado: (2019)

Ultrasonographic Evaluation of Parathyroid Hyperplasia in Dialysis Patients
por: Pavlovic, Drasko, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ip0f1rcqrgsdieknfq16kg2l4e